We hereby announce that the study by TRANS GENIC INC. (hereinafter referred to as q‡weqˆ), which produced a high-affinity antibody using Ganp gene-transgenic mouse technology, has been published in q‡The Journal of Immunology (Volume 174),qˆ the world-famous academic journal in the field of immunology.

We conducted the collaborative research with Nobuo Sakaguchi, professor at faculty of medical and pharmaceutical sciences Kumamoto University, investor of this said technology since May, 2003,, and with Kumamoto TLO, toward commercializing said technology under the q‡Grant for Practical Application of University R&D 2003qˆ by the New Energy and Industrial Technology Development Organization (NEDO)

IMMUNOKIK INC., the company co-founded by Dr. Sakaguchi and us, holds the patent to said technology (Patent Number: PCT/JP03/14221), and we have obtained exclusive license from IMMUNOKIK INC. to produce, use and distribute this technology. (Click here for further information.)

It was substantiated in the aforementioned publication that the HIV virus antibodies produced using said technology showed extremely higher affinity and neutralization activity than conventional antibodies.

This implies that said technology using the Ganp gene-transgenic mouse is remarkably effective in producing distinguished antibodies that are applicable to the development of both diagnostic and therapeutic products.

In addition, this aforementioned publication is presented as a topic in q‡IN THIS ISSUEqˆ of q‡The Journal of Immunology, Volume.174.